Trial · NCT07261657
N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
NCT07261657, Early phase 1, Recruiting, Seth Pollack
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy. Trials, record NCT07261657. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07261657
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
- NCT number
- NCT07261657
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 8 participants, estimated
- Lead sponsor
- Seth Pollack
- Conditions
- Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
- Interventions
- Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept, X-Ray Imaging
- First posted
- 2025-12-03
- Last updated
- 2026-08-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The expansion of rare persisting transferred T-cell receptor therapy | Before and after eight weeks of N-803 therapy | Will be assessed using T-cell receptor sequencing or flow cytometry. |
| Primary | Incidence of adverse events | Up to 30 days after the last administration of N-803 | Will be determined by the incidence, severity, and attribution of adverse events graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
| Secondary | Overall response rate | Up to 4 years | Will be defined by Response Evaluation Criteria in Solid Tumors version 1.1. Will be estimated with a two-sided 95% confidence interval using the Clopper-Pearson method. |
| Secondary | Six-month progression-free survival (PFS) | Up to 4 years | Defined as the proportion of patients who remain alive and progression-free at six months (± 2 weeks) from treatment initiation. The Kaplan-Meier method will be used to estimate the six-month PFS rate, and a corresponding 95% confidence interval will be reported. |
| Secondary | Median PFS | Up to 4 years | Kaplan-Meier curves will be reported descriptively, and median PFS will only be interpreted if the survival function drops below 50% with sufficient events to support stable estimation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | PLATANIAS, LEONIDAS C. | NORTHWESTERN UNIVERSITY | NATIONAL CANCER INSTITUTE | 1993 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07261657
GET https://conductscience.org/api/trials/v1/NCT07261657/registered